Influence of abnormal metabolism on liver fibrosis in patients with chronic hepatitis B

doi:10.3877/cma.j.issn.1674-1358.2016.05.006

Abstract

Abstract:

Objective

To analyze the influence of abnormal metabolism on liver fibrosis in patients with chronic hepatitis B.

Methods

The influence factors on liver fibrosis by abnormal metabolism including HOMA-IR, HOMA-β, abnormal glucose and lipid metabolism, fatty liver disease were analyzed in 110 cases with chronic hepatitis B by the prospective cross-section research.

Results

The liver stiffness mesurement (LSM) was higher (F = 5.559, P = 0.005) for patients with higher HOMA-IR. The levels of indicators of liver function and TBil also increased with HOMA-IR, but with no significant differences (P > 0.05). With worse HOMA-β, the LSM was higher (t =-2.771, P = 0.029). The levels of indicators of liver function and TBil also increased along with HOMA-β, but with no significant differences (P > 0.05). Along with worse glucose metabolism condition, the LSM, ALP, GGT were higher, the proportion of fatty liver disease was higher (F = 4.663, 10.171, 11.331, 6.482; P = 0.033, 0.002, 0.001, 0.039). The levels of other indicators of liver function and TBil also increased along with worse glucose metabolism condition, but with no significant differences (P > 0.05). The levels of indicators of liver function, TBil and LSM were higher in abnormal lipid group or fatty liver disease group than that in normal lipid group or nonfatty liver disease group, but with no significant differences (P > 0.05).

Conclusions

Among patient with chronic hepatitis B, the insulin resistance, worse island beta cell function, worse glucose and lipid metabolism condition could promote progress of the liver fibrosis.

Key words: Chronic hepatitis B, Hemeostasis model assement of insulin resistance (HOMA-IR), Hemeostasis model assement of βcells (HOMA-β), Glucose metabolism abnormal, Lipid metabolism abnormal, Fatty liver, Liver fibrosis

Dafeng Liu, Yaling Liu, Yilan Zeng, Lin Wang, Jun Lin, Li Wang, Rong Hu, Lijuan Lan, Yong Wang, Yi Xin, Xinhua Hu, Lei Bao. Influence of abnormal metabolism on liver fibrosis in patients with chronic hepatitis B[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(05): 541-545.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2016.05.006

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2016/V10/I05/541

Figures/Tables 4

References 25

1	Romero-Gomez M. Insulin resistance and hepatitis C[J]. world J Gastroenterol,2006:12(44):7075-7080.
2	Tsochatzis E, Papatheodoridis GV, Manesis EK, et al. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther,2008,27(1):80-89
3	刘大凤，冉兴无，王林, 等. 病毒性肝炎合并糖尿病的流行病学特征分析[J/CD]. 中华实验和临床感染病杂志:电子版,20126(2):121-124.
4	刘大凤，冉兴无，王林, 等. 糖尿病合并病毒性肝炎的临床分析[J]. 中国糖尿病杂志,2013,21(12):1112-1114.
5	刘大凤，曾义岚，林军, 等. 慢性乙型肝炎患者代谢异常的表现形式分析[J]. 成都医学院学报,2014,9(4):712-716.
6	兰丽娟，张碧英，刘大凤, 等. 不同糖代谢状态的慢性乙型肝炎患者肝脏炎症及纤维化的差异分析[J/CD]. 中华实验和临床感染病杂志:电子版,2015,9(5):322-325.
7	刘大凤，刘亚玲，张鸿, 等. 慢性乙型肝炎患者影响肝纤维化的主要代谢因素分析[J/CD]. 中华实验和临床感染病杂志:电子版,2015,9(3):630-635.
8	胡芯华，张霞，刘大凤, 等. 乙肝病毒对慢性乙肝患者代谢参数的关联性分析[J]. 成都医学院学报,2016,11(1):31-34.
9	中华医学会传染病与寄生虫学会，肝病学分会. 病毒性肝炎防治方案[J]. 中华肝脏病杂志,2000,8(3):324-329.
10	中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南: 2010年版[J]. 中华肝脏病杂志,2011,19(1):13-24.
11	中华医学会糖尿病学分会. 中国2型糖尿病防治指南: 2010年版[J]. 中国糖尿病杂志,2012,20(1):S1-S37.
12	刘力生. 中国高血压防治指南: 2010[J]. 中国高血压杂志,2011,19(8):701-708.
13	中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志,2007,35(5):390-419.
14	Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C[J]. Gastroenterology,2005,128(2):343-350.
15	程小飞，梁雄波，熊晓青, 等. 肝硬化门静脉高压患者门静脉压力与FibroScan检测值相关性分析[J]. 临床肝胆病杂志,2015,31(3):381-383.
16	程晓静，陆伟，侯伟, 等. FibroTest联合FibroScan对慢性乙型肝炎肝纤维化的诊断价值[J]. 临床肝胆病杂志,2014,30(5):424-427.
17	张丽涓，王志毅，张大志, 等. 瞬时弹性波扫描仪检查在慢性乙型肝炎肝纤维化患者中的应用[J]. 重庆医科大学学报,2011,36(6):721-724.
18	Mohammad Alizadeh AH, Fallahian F, Alavian SM, et al. Insulin resistance in chronic hepatitis B and C[J]. Indian J Gastroenterol,2007,25(6):286-289.
19	杨德华，曾义岚，刘大凤, 等. 慢性乙型肝炎患者Fibroscan弹性值的影响因素分析[S]. 第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议论文汇编. 2013:160-166
20	刘大凤，曾义岚，杨德华, 等. 慢性乙肝患者Fibroscan弹性值与胰岛素抵抗的相关性分析[S]. 第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议论文汇编,2013:166-172.
21	张鸿，刘大凤，曾义岚, 等. 慢性乙肝Fibroscan弹性值与代谢参数的相关性分析[J]. 成都医学院学报,2013,8(1):35-38.
22	Kettaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients[J]. J Hepatol,2007,46(4):628-634.
23	Sirli R, Sporea I, Bota S, et al. Factors influencing reliability of liver stiffness measurements using transient elastography (M-probe)-monocentric experience[J]. Eur J Radiol,2013,82(8):e313-e316.
24	Zheng RD, Xu CR, Jiang L, et al. Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis[J]. Inter J Med Sci,2010,7(5):272-277.
25	Sakugawa H, Nakayoshi T, Kobashigawa K, et al. Metabolic syndrome is directly associated with gamma glutamyl transpeptidase elevation in Japanese women[J]. World J Gastroenterol,2004,10(7):1052-1055.

指标	HOMA-IR ≤ 1	2 ≥ HOMA-IR > 1	HOMA-IR> 2	统计量	P值
脂肪肝（有/无，%）	4/41（8.89）	8/41（16.33）	4/12（25.00）	χ² = 2.606	0.272
^aALT（±s，U/L）	51.23±2.20	62.10±1.78	59.42±2.12	F = 0.901	0.409
^aAST（±s，U/L）	93.01±1.43	93.24±1.54	106.98±1.43	F = 0.425	0.655
^aALP（±s，U/L）	45.03±2.73	59.23±2.38	74.03±2.17	F = 0.857	0.427
^aGGT（±s，U/L）	16.20±1.60	17.70±1.51	20.49±1.53	F = 2.046	0.134
^aTBil（±s，μmol/L）	16.20±1.60	17.70±1.51	20.49±1.53	F = 3.367	0.069
^aLSM（±s，kPa）	8.81±2.13	11.76±2.11	17.49±1.76	F = 5.559	0.005

指标	HOMA-IR ≤ 1	2 ≥ HOMA-IR > 1	HOMA-IR> 2	统计量	P值
脂肪肝（有/无，%）	4/41（8.89）	8/41（16.33）	4/12（25.00）	χ² = 2.606	0.272
^aALT（±s，U/L）	51.23±2.20	62.10±1.78	59.42±2.12	F = 0.901	0.409
^aAST（±s，U/L）	93.01±1.43	93.24±1.54	106.98±1.43	F = 0.425	0.655
^aALP（±s，U/L）	45.03±2.73	59.23±2.38	74.03±2.17	F = 0.857	0.427
^aGGT（±s，U/L）	16.20±1.60	17.70±1.51	20.49±1.53	F = 2.046	0.134
^aTBil（±s，μmol/L）	16.20±1.60	17.70±1.51	20.49±1.53	F = 3.367	0.069
^aLSM（±s，kPa）	8.81±2.13	11.76±2.11	17.49±1.76	F = 5.559	0.005

指标	HOMA-β ≥ 100	HOMA-β < 100	t值	P值
^aALT（U/L）	63.38±2.00	56.64±2.01	0.383	0.703
^aAST（U/L）	39.71±1.38	50.59±1.70	-1.108	0.270
^aALP（U/L）	76.72±1.39	96.30±1.48	-1.392	0.167
^aGGT（U/L）	42.35±1.41	55.55±2.58	-0.696	0.488
^aTBil（μmol/L）	17.09±1.36	17.47±1.57	-0.118	0.906
^aLSM（kPa）	6.57±1.57	11.41±2.14	-2.771	0.029

指标	HOMA-β ≥ 100	HOMA-β < 100	t值	P值
^aALT（U/L）	63.38±2.00	56.64±2.01	0.383	0.703
^aAST（U/L）	39.71±1.38	50.59±1.70	-1.108	0.270
^aALP（U/L）	76.72±1.39	96.30±1.48	-1.392	0.167
^aGGT（U/L）	42.35±1.41	55.55±2.58	-0.696	0.488
^aTBil（μmol/L）	17.09±1.36	17.47±1.57	-0.118	0.906
^aLSM（kPa）	6.57±1.57	11.41±2.14	-2.771	0.029

指标	NGT组	IGT组	DM组	统计量	P值
脂肪肝（有/无，%）	6/65（9.23）	3/6（33.33）	7/23（30.33）	χ² = 6.482	0.039
^aALT（±s，U/L）	58.25±2.02	67.67±1.89	51.78±2.01	F = 0.464	0.497
^aAST（±s，U/L）	48.60±1.63	52.30±1.59	52.39±1.83	F = 0.465	0.497
^aALP（±s，U/L）	86.54±1.42	123.18±1.41	110.17±1.52	F = 10.171	0.002
^aGGT（±s，U/L）	43.55±2.35	93.05±2.58	80.26±2.51	F = 11.331	0.001
^aTBil（±s，μmol/L）	16.37±1.59	20.66±1.51	19.29±1.46	F = 3.384	0.069
^aLSM（±s，kPa）	9.71±2.11	13.81±2.55	13.58±2.02	F = 4.663	0.033

Please choose a citation manager

Content to export